Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
| Status: | Completed |
|---|---|
| Conditions: | Allergy, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Otolaryngology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 8/30/2018 |
| Start Date: | March 2015 |
| End Date: | August 2016 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients
The primary objectives of the study are to evaluate the effects of two doses of nalbuphine
HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in
patients with prurigo nodularis and to evaluate the safety and tolerability in the study
population.
HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in
patients with prurigo nodularis and to evaluate the safety and tolerability in the study
population.
Inclusion Criteria:
- Subject suffering from generalized prurigo nodularis
- Have demonstrated pruritus intensity during screening
- Male or female who are at least 18 years old at the time of consent
Exclusion Criteria:
- Subject has chronic pruritus resulting from other conditions
- Subject has a history of substance abuse within the past year
- Subject has a known drug allergy to opioids
- Subject is a pregnant or lactating female
We found this trial at
3
sites
10900 Euclid Ave
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216-368-2000
Principal Investigator: Neil Korman
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
Click here to add this to my saved trials
Temple University Hospital On January 18, 1892 a three-story house at 3403 North Broad Street...
Click here to add this to my saved trials